Wells Fargo
CADX

Wells Fargo’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Wells Fargo’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-84,856
Closed -$768K – 6343
2013
Q4 		$768K Buy
84,856
+8,474
+11% +$61.2K ﹤0.01% 3574
2013
Q3 		$481K Buy
76,382
+63,682
+501% +$405K ﹤0.01% 3782
2013
Q2 		$87K Buy
+12,700
New +$88.5K ﹤0.01% 4442

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo's CADX Position: Q1 2014 in Review

Wells Fargo sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 84,856 shares — an estimated $768K sold.

Wells Fargo first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $768K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Wells Fargo reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Wells Fargo sold 84,856 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $768K.
  • Wells Fargo first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Wells Fargo's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $768K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Wells Fargo's 13F filing for Q1 2014, filed 12 May 2014.